Item 8.01. Other Events.

On September 10, 2012, Amgen Inc. (the "Company") priced an offering of €675,000,000 aggregate principal amount of Senior Notes due 2019 (the "2019 Notes") and £700,000,000 aggregate principal amount of Senior Notes due 2029 (the "2029 Notes," and together with the 2019 Notes, the "Notes"). The Notes are being sold outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the "Securities Act"). The Notes have not been and will not be registered under the Securities Act and may not be offered or sold within the United States. Interest on the 2019 Notes will be paid in cash annually in arrears at rate of 2.125% per annum, and interest on the 2029 Notes will be paid in cash annually in arrears at rate of 4.000% per annum. The Notes will be issued pursuant to an indenture, dated as of August 4, 2003, between the Company and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, and an officers' certificate setting forth the terms of the Notes. Settlement for the offering is expected to occur on September 13, 2012, subject to the execution of a subscription agreement for the Notes and the satisfaction of customary closing conditions.

---